Long-term Persistence of Hepatitis B and Pertussis Antibody Responses in Healthy 4- to 5 Year Old Children Previously Vaccinated With a 2-dose or 3-dose Infants Series and Toddler Dose With VAXELIS or INFANRIX Hexa

Trial Profile

Long-term Persistence of Hepatitis B and Pertussis Antibody Responses in Healthy 4- to 5 Year Old Children Previously Vaccinated With a 2-dose or 3-dose Infants Series and Toddler Dose With VAXELIS or INFANRIX Hexa

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Oct 2017

At a glance

  • Drugs Hib-DTaP-hepatitis B-poliovirus vaccine (Primary) ; Hib DTaP hepatitis B poliovirus vaccine (Infanrix hexa)
  • Indications Diphtheria; Haemophilus infections; Hepatitis B; Pertussis; Poliomyelitis; Tetanus
  • Focus Pharmacodynamics; Registrational
  • Sponsors MCM Vaccine; sanofi pasteur
  • Most Recent Events

    • 06 Mar 2017 Time frame of primary end point has been changed from At approx. 4 years of age to Day 1 and phase also changed from 3 to phase 4.
    • 06 Mar 2017 Status changed from active, no longer recruiting to completed.
    • 29 Jul 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top